FDA Recalls Akorn Gonak Eye Drops for Manufacturing Deviations
Akorn, Inc. recalled all lots of Gonak Hypromellose Ophthalmic Solution distributed in the USA and Puerto Rico after the firm ceased operations and could not complete required stability studies.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This recall involves a risk-of-harm product (ophthalmic solution with incomplete stability studies) where no patient injuries or illnesses have been reported. Per the severity rubric, this classification corresponds to Score 3 / High.
Plain-English summary
Akorn, Inc. is recalling all lots of Gonak Hypromellose Ophthalmic Solution 25mg/mL in 15 mL bottles, distributed nationwide in the USA and Puerto Rico.
The recall was issued due to Current Good Manufacturing Practice (CGMP) deviations. The firm went out of business and could no longer continue the stability studies for the product.
The recalled product
- Product
- Gonak Hypromellose Ophthalmic Solution 25mg/mL, 15 mL bottles, Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Part of a larger recall action
This product is one of 86 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 86 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · manufacturing deviation
See all →- HighBaxter Recalls Vancomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
Similar recalls
- ModerateFDA recalls GONAK ophthalmic drug solution for manufacturing deviations
FDA (Drugs) · 2023-01-25
- HighProparacaine Ophthalmic Solution Recalled for Manufacturing Quality Deviations
FDA (Drugs) · 2023-01-25
- ModerateDrug recall: Proparacaine eye solution due to manufacturing deviations
FDA (Drugs) · 2023-01-25
- HighPrescription Eye Drops Recalled for Manufacturing Control Deviations
FDA (Drugs) · 2023-01-25
- ModerateCiprofloxacin ophthalmic solution recalled for manufacturing practice deviations
FDA (Drugs) · 2023-01-25
- ModeratePrescription eye drop recall due to manufacturing compliance issues
FDA (Drugs) · 2023-01-25